A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

BACKGROUND: Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic rena...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yang, James C., Haworth, Leah, Sherry, Richard M., Hwu, Patrick, Schwartzentruber, Douglas J., Topalian, Suzanne L., Steinberg, Seth M., Chen, Helen X., Rosenberg, Steven A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2003
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2275324/
https://ncbi.nlm.nih.gov/pubmed/12890841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa021491
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia